Ajugol primarily mitigates AD pathology by regulating the TLR/NF-κB/NLRP3 inflammasome pathway and the BCL-2/BAX/cytochrome C/caspase-3 apoptosis pathway, thereby reducing neuroinflammation and neuronal death. Here, BCL2 is linked to Alzheimer disease.